



Canadian Association  
for **Porphyrria**

Association Canadienne  
de **Porphyrie**

# Presentation to CBS Board of Directors Part III June 27, 2018

Presenter: Wendy Sauvé, Co-President, CAP/ACP



Canadian Association  
for **Porphyria**

Association Canadienne  
de **Porphyrie**

# About Porphyria

**Porphyria** is a rare, metabolic disorder occurring in 1/20,000. Of those, 1/50 will present with symptoms requiring treatment.

## Symptoms

Patients with acute porphyria often present with excruciating abdominal pain. If untreated, it can progress to convulsions and paralysis. Porphyria can be life-threatening.

## Treatment

The **only** treatment for acute porphyria is a blood product called hemin. Panhematin was the first orphan drug approved in the US in 1983.




Canadian Association  
for **Porphyrria**


Association Canadienne  
de **Porphyrrie**

# Hemin Distribution

## Current



## Proposed



\* Héma-Québec has been successfully distributing hemin since  
2011



# CBS Process of Review

Figure 1 – Plasma Product Selection Process




Figure 1 – Plasma Product Selection Process (Cont'd)




Figure 1 – Plasma Product Selection Process (Cont'd)





Figure 1 – Plasma Product Selection Process (Cont'd)



## CBS PLASMA PRODUCT SELECTION PROCESS - Process Summary



Canadian Association  
for **Porphyria**

Association Canadienne  
de **Porphyrie**

# CAP Review of the Process



Provincial/Territorial Blood Liaison Committee



Dr. Graham Sher, CEO



# CBS Process of Review

Figure 1 – Plasma Product Selection Process




Figure 1 – Plasma Product Selection Process (Cont'd)




Figure 1 – Plasma Product Selection Process (Cont'd)





Figure 1 – Plasma Product Selection Process (Cont'd)



## CBS PLASMA PRODUCT SELECTION PROCESS - Process Summary